In a report released on May 8, Mike Kratky from Leerink Partners reiterated a Buy rating on Insulet (PODD – Research Report), with a price target of $333.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mike Kratky has given his Buy rating due to a combination of factors that highlight Insulet’s strong performance and potential for future growth. The company reported impressive first-quarter results, surpassing market expectations with worldwide Omnipod sales increasing by 4% compared to consensus estimates. Notably, Insulet raised its guidance for worldwide Omnipod constant currency sales growth, indicating confidence in its ability to maintain momentum.
Furthermore, Insulet’s commitment to expanding its market share is evident through its focus on the T2 diabetes segment, which accounted for a significant portion of new patient starts. The company also demonstrated strong operational efficiencies, with improved gross margins and adjusted EBIT margins. These positive dynamics, coupled with favorable market conditions and increasing profitability, suggest that Insulet is well-positioned for continued success, justifying the Buy rating.
In another report released on May 9, Piper Sandler also maintained a Buy rating on the stock with a $310.00 price target.
PODD’s price has also changed slightly for the past six months – from $268.000 to $257.000, which is a -4.10% drop .
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue